Opendata, web and dolomites

GlycoMabs SIGNED

Chemoenzymatic glyco-engineering of therapeutic monoclonal antibodies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 GlycoMabs project word cloud

Explore the words cloud of the GlycoMabs project. It provides you a very rough idea of what is the project "GlycoMabs" about.

act    chemical    opportunity    obtain    gained    antibodies    mediated    arsenal    molecular    cancer    precise    construct    carbohydrate    specificity    basis    chemoenzymatic    biology    mabs    elucidate    therapeutic    defucosylation    contributes    igg    explore    place    treatment    fcgriiia    biopharmaceutical    mechanisms    alfc    generate    homogeneous    engineering    active    glycomabs    fucosidase    synthesis    skills    lack    asn297    immune    strategies    simplify    fragment    position    glycan    altogether    antibody    excellent    linked    glycosylated    biosuperior    host    potency    cells    afucosylated    residue    modulates    laboratory    glycoengineering    expertise    structure    lacking    mixture    industry    affinity    drugs    homogenous    core    glycoproteins    containing    functions    glycoforms    crystallisable    generation    engineer    grant    me    structural    stablished    domain    tailor    clinical    endos    enzyme    site    fucose    glycoengineered    commercialized    secondment    ema    conserved    glycosylation    anticancer    approved    fc    intersectoral    career    reactions    enzymes    independent    monoclonal    effector    protein    structures    igg1    learning   

Project "GlycoMabs" data sheet

The following table provides information about the project.

Coordinator
ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS 

Organization address
address: PARQUE TECNOLOGICO EDIFICIO 801 A
city: DERIO VIZCAYA
postcode: 48160
website: www.cicbiogune.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 160˙932 €
 EC max contribution 160˙932 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-RI
 Starting year 2019
 Duration (year-month-day) from 2019-04-16   to  2021-04-15

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS ES (DERIO VIZCAYA) coordinator 160˙932.00

Map

 Project objective

Monoclonal Antibodies (mAbs) have gained an important place in the therapeutic arsenal of anticancer drugs. mAbs are glycoproteins containing a conserved N-linked glycosylation site at residue Asn297 of the fragment crystallisable (Fc). Most of the mAbs approved by the EMA are commercialized as a complex mixture of glycoforms at this site. It is well stablished that the precise chemical structure of the N-linked glycan modulates the effector functions mediated by the Fc domain. Specifically, for cancer treatment applications, the lack of fucose on the glycan structure contributes to enhance the effector functions of the antibodies, via increased affinity of IgG1 for FcgRIIIa on immune cells. New strategies to glycoengineering mAbs with homogenous glycoforms and lacking fucose core on their glycan structures have become a priority for the biopharmaceutical industry in order to obtain “biosuperior” anticancer drugs. Here, we will engineer a novel fucosidase enzyme that can act on fully glycosylated mAbs in order to simplify the chemoenzymatic synthesis of antibody drugs, based on the host laboratory expertise in Carbohydrate Active Enzymes. We will address three specific aims: (1) to define the structural basis of EndoS antibody specificity; (2) to elucidate the molecular mechanisms of IgG defucosylation by AlfC; and (3) to engineer an enzyme with fucosidase activity and specific for IgG. The GlycoMabs project will provide me an excellent and unique career opportunity by learning new skills in structural biology, protein engineering and project management which will grant me a leading independent position. Moreover, I will explore the industry interest in the application of our novel enzymes to generate homogeneous and afucosylated antibodies through an intersectoral secondment. Altogether, we will contribute to construct the next generation of therapeutic glycoengineered mAbs to tailor the immune reactions and increase their clinical potency.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GLYCOMABS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GLYCOMABS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MultiSeaSpace (2019)

Developing a unified spatial modelling strategy that accounts for interactions between species at different marine trophic levels, and different types of survey data.

Read More  

MOSAiC (2019)

Multimode cOrrelations in microwave photonics with Superconducting quAntum Circuits

Read More  

EGeoCC (2019)

Ethnic geography and civil conflict

Read More